Iniciación a asuntos Regulatorios.II EDición
BIOTEC. PROYECTO DE INNOVACIÓN
BIOTEC PROJECT: empresa nacional, spin off de una universidad española con proyecto de I+D puro. Innovación en el campo de la oncología y enfermedades neurodegenerativas. Largo pipeline de productos en investigación. Uno de ellos avanzado hasta IMPD y solicitud de ensayos clínicos en humanos, fase I. Gran equipo de investigación a nivel internacional con importantes key opinion leaders. Requieren inversores que aporten al proyecto inyección de capital con prima de emisión entre los 2 y los 30 M€ para afrontar las siguientes fases del desarrollo. Derechos y compromiso del inversor para comercialización efectiva en diferentes países en función de la inversión. Posibilidad de combinar fondos de inversión y algún socio industrial.
OPPORTUNITY TO ACQUIRE A SMALL SPANISH COMPANY.- PERFECT FOR ENTERING SPANISH PHARMA MARKET AND/OR FOR THOSE INVESTORS PURSUING TO ENTER THIS BUSINESS SECTOR
A small sized and young company, situated in Madrid Region, closed to International Airport is FOR SALE. The company is specialized in OTC/Health Products, Skin-Care dedicated, with a growing turnover about 1 million Euros in 2011 and with positive EBITDA. The company is a perfect kick off track for starting up businesses in Spain in Health Care Sector at a minimum risk and cost. The transaction includes an industrial facility valued by 900.000 Euros, with all the suitable permissions for being pharmaceutical warehouse and shipping centre. Those requesting further information and the selling memorandum, please, send an e-mail to angel.calvo@qualitecfarma.com, with a brief description of themselves.
Service
D. Ángel Calvo
Director general de StratecFarma
He has a background in Chemistry and Biotechnology, as well as in Business Administration. He has developed his entire career in the Healthcare Business.
In the late 80´s and first 90´s he occupied executive positions in international companies such as Hofmann-La Roche and Pharmacia, both in the Hospital and Retail Pharma Business, as well as in Diagnostics. In the late 90s he established Pharmastrategy SL, a consulting company that was the origin of his own pharmaceutical company ACYPHARMA / ACYFABRIK, afterwards acquired by Pliva DD.
Since 2000, he has been dedicated to the generics and OTC field in Southern Europe, having started upand managed several affiliates of multinational companies, such as Pliva, Dr. Reddy´s and Actavis, having contributed from the very beginning to build the generics industry in Spain. He has participated in many transactions: companies selling out and acquisitions, as well as mergers, and products in and out licensing. He publishes annually “ Generics in Spain, Practical Guide, Retail and Hospitals” the definitive most extended report on the Pharma market in Spain, available at QualitecFarma® website.